Miller K, Bergmann L, Gschwend J, Keilholz U
Klinik für Urologie, Charité - Universitätsmedizin Berlin, Germany.
Aktuelle Urol. 2011 Jul;42(4):242-6. doi: 10.1055/s-0031-1271548. Epub 2011 Jun 30.
With the introduction of targeted drug therapies, a paradigm shift for the treatment of metastatic renal cell carcinoma has taken place. New compounds like sunitinib, sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards to replace the use of cytokines as standard therapy. Recently, these substances have been complemented by everolimus and pazopanib. An interdisciplinary consensus conference was held to discuss which criteria to consider when using these drugs (treatment sequence) and what questions remain unanswered based on the current study situation (open questions). Results from the 2009 conference provided the basis for the 2010 meeting. The results of the 2010 conference are presented as short theses.
随着靶向药物疗法的引入，转移性肾细胞癌的治疗模式发生了转变。舒尼替尼、索拉非尼、贝伐单抗和替西罗莫司等新化合物已成为新的治疗标准，取代了细胞因子作为标准疗法的使用。最近，依维莫司和帕唑帕尼也加入了这些药物的行列。召开了一次跨学科共识会议，讨论使用这些药物时应考虑哪些标准（治疗顺序），以及根据当前研究情况仍有哪些问题未得到解答（未决问题）。2009年会议的结果为2010年会议提供了基础。2010年会议的结果以简短论文的形式呈现。
